{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T06:07:19Z","timestamp":1784700439320,"version":"3.55.0"},"reference-count":63,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Rare disease patients, who collectively number over 400 million worldwide, remain systematically underserved within existing universal health coverage frameworks. Orphan drug market exclusivity is a widely adopted regulatory incentive designed to stimulate pharmaceutical innovation for rare diseases. Recent regulatory reforms in China, the United States, and the European Union have introduced conditional mechanisms, signaling a shift from static proprietary protection toward a conditional regulatory governance model. Japan, while not undertaking legislative reform in 2026, offers a distinct reference point through its re-examination system. To date, no study has systematically integrated these latest legislative reforms into a comparative regulatory analysis or examined how the institutional design of orphan drug exclusivity can be calibrated to balance innovation incentives with equitable patient access.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study employs an integrated multi-method approach combining comparative legal analysis, doctrinal interpretation, evidence-based policy evaluation, and case analysis. A structured analytical framework is constructed around four key regulatory dimensions\u2014eligibility criteria, exclusivity duration, scope of protection, and exception mechanisms. Using this framework, the study compares the orphan drug exclusivity regimes of the United States, the European Union, and Japan, and assesses the institutional risks embedded in China's newly enacted legislation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>This article proposes a novel theoretical model that reconceptualizes orphan drug market exclusivity as a conditional public-law entitlement whose legitimacy is premised on the continuing fulfillment of public health objectives. Applying this framework, the study identifies four core structural deficiencies in China's current regime and, drawing on mature comparative practices, develops targeted institutional design proposals for each regulatory dimension.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Reconceiving orphan drug market exclusivity as a conditional public-law entitlement, rather than as an intellectual property right, offers a sustainable governance pathway for reconciling innovation incentives with the equity and financial protection goals of universal health coverage. Embedding conditional constraints into pharmaceutical exclusivity rules ensures that regulatory incentives serve long-term public health objectives and carries implications for addressing market failures and access challenges in other areas of global public health.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1896433","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T05:56:07Z","timestamp":1784699767000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Reconceiving orphan drug market exclusivity as a conditional public-law entitlement: a sustainable regulatory governance model with comparative lessons for China"],"prefix":"10.3389","volume":"13","author":[{"given":"Guiyu","family":"Quan","sequence":"first","affiliation":[{"name":"School of Law, Sichuan Agricultural University","place":["Ya'an, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhou","sequence":"additional","affiliation":[{"name":"School of Law, Sichuan Agricultural University","place":["Ya'an, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Liu","sequence":"additional","affiliation":[{"name":"School of Management, Sichuan Agricultural University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinan","family":"Wu","sequence":"additional","affiliation":[{"name":"School of Law, Sichuan Agricultural University","place":["Ya'an, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Yan","sequence":"additional","affiliation":[{"name":"School of Law, Sichuan Agricultural University","place":["Ya'an, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"key":"B1","volume-title":"Implementing Regulations of the Drug Administration Law of the People\u2018s Republic of China","year":"2026"},{"key":"B2","unstructured":"Consolidated Appropriations Act, 2026, Pub. L. No. 119-75, \u00a7 6605\n          \n          2026"},{"key":"B3","unstructured":"Proposal for a Regulation of the European Parliament and of the Council on the Reform of the EU Pharmaceutical Legislation, ST-6366-2026-INIT\n          \n          2026"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1003-0476.2026.02.004","author":"Zhang","year":"2026","journal-title":"From General Protection of Intellectual Property Rights to Industry-Specific Customization: Theoretical Evidence and Institutional Construction of Exclusive Rights in the Rare Disease Drug Market"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e57353","DOI":"10.2196\/57353","article-title":"Patterns of the health and economic burden of 33 rare diseases in China: Nationwide web-based study","volume":"10","author":"Yu","year":"2024","journal-title":"JMIR Public Health Surveill"},{"key":"B6","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13023-018-0990-4","article-title":"Estimating the clinical cost of drug development for orphan versus non-orphan drugs","volume":"14","author":"Jayasundara","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e15701638379700","DOI":"10.2174\/0115701638379700250713040806","article-title":"The economics of drug development: a comparison between orphan and non-orphan drugs","volume":"23","author":"Gomase","year":"2026","journal-title":"Curr Drug Discov Technol"},{"key":"B8","unstructured":"DrugBank\n              Team\n            \n          \n          Navigating the Orphan Drug Ecosystem. DrugBank Blog\n          \n          2025"},{"key":"B9","unstructured":"Don't close the door on rare disease research\n          \n          \n            \n              Ybarra\n            \n            \n              M\n            \n          \n          PhRMA Blog\n          \n          2023"},{"key":"B10","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/s41431-019-0508-0","article-title":"Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database","volume":"28","author":"Nguengang Wakap","year":"2020","journal-title":"Euro J Human Genet"},{"key":"B11","volume-title":"Illness Challenge, 2026 China Rare Disease Industry Trend Observation Report","year":"2026"},{"key":"B12","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1186\/s13023-025-03933-8","article-title":"Spectrum and epidemiology of rare diseases in a Chinese natural population of 14","volume":"20","author":"Li","year":"2025","journal-title":"Orphanet J Rare Dis"},{"key":"B13","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1186\/s13023-021-01901-6","article-title":"Using four decades of FDA orphan drug designations to describe trends in rare disease drug development: substantial growth seen in development of drugs for rare oncologic, neurologic, and pediatric-onset diseases","volume":"16","author":"Miller","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"B14","unstructured":"Major Change for Rare Disease Treatments on Way, Signals MHRA\n          \n          2025"},{"key":"B15","unstructured":"White III Institute. Rare Diseases 101\n          \n          \n            \n              Augustus\n              A\n            \n          \n          AAW Institute\n          \n          2025"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e341","DOI":"10.1016\/S2214-109X(24)00056-1","article-title":"The landscape for rare diseases in 2024","volume":"12","year":"2024","journal-title":"Lancet Glob Health."},{"key":"B17","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1056\/NEJMp058317","article-title":"Adopting orphan drugs \u2014 two dozen years of treating rare diseases","volume":"354","author":"Haffner","year":"2006","journal-title":"N Engl J Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1186\/s13023-024-03398-1","article-title":"Expediting treatments in the 21st century: orphan drugs and accelerated approvals","volume":"19","author":"Domike","year":"2024","journal-title":"Orphanet J Rare Dis"},{"key":"B19","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3969\/j.issn.1674-2982.2022.06.004","volume":"15","author":"Wang","year":"2022","journal-title":"Chin J Health Policy"},{"key":"B20","unstructured":"Orphan Drugs Market Report 2026\n          \n          2026"},{"key":"B21","unstructured":"Herman\n              C\n            \n          \n          The Orphan Drug Act at 30 Years: What\u2018s Next?\n          \n          2013"},{"key":"B22","unstructured":"Drug development \u2013 The success of orphan drugs\n          \n          BioStock\n          \n          2023"},{"key":"B23","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1093\/jlb\/lsy019","article-title":"Addressing the needs of Canadians with rare diseases: an evaluation of orphan drug incentives","volume":"5","author":"Harris","year":"2018","journal-title":"J Law Biosci."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-016-0551-7","article-title":"Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients' health needs?","volume":"12","author":"Rodriguez-Monguio","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"B25","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1080\/21678707.2022.2153671","article-title":"Making orphan drugs and services available and accessible for people who live with rare diseases: what has been done? A systematic scoping review","volume":"10","author":"Ghiasvand","year":"2022","journal-title":"Expert Opin Orphan Drugs."},{"key":"B26","author":"Mincarone","year":"2015","journal-title":"Reimbursed Price of Orphan Drugs: A Value Based Framework"},{"key":"B27","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/1750-1172-9-62","article-title":"Shining a light in the black box of orphan drug pricing","volume":"9","author":"Picavet","year":"2014","journal-title":"Orphanet J Rare Dis"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1016\/j.jval.2020.08.004","article-title":"Modifying the criteria for granting orphan drug market exclusivity","volume":"23","author":"Socal","year":"2020","journal-title":"Value Health"},{"key":"B29","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1377\/hlthaff.2023.00219","article-title":"Orphan drug label expansions: analysis of subsequent rare and common indication approvals","volume":"43","author":"Miller","year":"2024","journal-title":"Health Aff."},{"key":"B30","doi-asserted-by":"publisher","first-page":"26","DOI":"10.53292\/2d3a6004.61d4cd94","author":"Bostyn","year":"2022","journal-title":"Sub-Setting and Indication Stacking in Orphan Drugs: A Recipe for the Future of Exclusive Rights"},{"key":"B31","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1007\/s40258-023-00832-6","article-title":"Prices of orphan drugs in four western European countries before and after market exclusivity expiry: a cross-country comparison of list prices and purchase prices","volume":"21","author":"Dane","year":"2023","journal-title":"Appl Health Econ Health Policy"},{"key":"B32","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.jval.2025.03.004","article-title":"Twenty-four years after the launch of the eu orphan regulation: analyzing dutch price dynamics, biosimilars, and generics for orphan medicinal products","volume":"28","author":"van den Berg","year":"2025","journal-title":"Value Health"},{"key":"B33","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13023-025-03634-2","article-title":"Debates over orphan drug pricing: a meta-narrative literature review","volume":"20","author":"Hanchard","year":"2025","journal-title":"Orphanet J Rare Dis."},{"key":"B34","unstructured":"The orphan drug act: how the FDA unlawfully usurped market exclusivity\n          \n          \n            \n              Kim\n              S\n            \n          \n          Northwest. J. Technol. Intell. Prop.\n          \n          2013"},{"key":"B35","doi-asserted-by":"publisher","first-page":"e074982","DOI":"10.1136\/bmj-2023-074982","article-title":"Pharmaceutical governance system for costly drugs through human rights due diligence","volume":"391","author":"Lemmens","year":"2025","journal-title":"BMJ"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1093\/grurint\/ikaf034","article-title":"Pharmaceutical data and market exclusivity: mechanism and enforceability of regulatory exclusivities","volume":"74","author":"Stief","year":"2025","journal-title":"GRUR Int."},{"key":"B37","doi-asserted-by":"publisher","first-page":"100870","DOI":"10.1016\/j.hlpt.2024.100870","article-title":"Societal preferences for granting orphan drugs special status in reimbursement decisions","volume":"13","author":"Reckers-Droog","year":"2024","journal-title":"Health Policy Technol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1278710","DOI":"10.3389\/fphar.2024.1278710","article-title":"Orphan drug policy analysis in China","volume":"15","author":"Liu","year":"2024","journal-title":"Front Pharmacol"},{"key":"B39","volume-title":"Implementing Regulations of the Drug Administration Law of the People's Republic of China (Revised Draft for Comments)","year":"2022"},{"key":"B40","doi-asserted-by":"publisher","first-page":"89","DOI":"10.5582\/irdr.2019.01066","article-title":"Incidence and prevalence of 121 rare diseases in China: Current status and challenges","volume":"8","author":"He","year":"2019","journal-title":"Intractable Rare Dis Res"},{"key":"B41","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1111\/j.1468-0009.2011.00636.x","article-title":"An empirical review of major legislation affecting drug development: past experiences, effects, and unintended consequences","volume":"89","author":"Kesselheim","year":"2011","journal-title":"Milbank Q."},{"key":"B42","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/j.jval.2024.12.009","article-title":"Rare disease policy in high-income countries: an overview of achievements, challenges, and solutions","volume":"28","author":"Gentilini","year":"2025","journal-title":"Value Health."},{"key":"B43","doi-asserted-by":"publisher","first-page":"93","DOI":"10.13723\/j.yxysh.2023.06.017","article-title":"Research on the requirements for granting a market exclusive period to rare disease drugs","volume":"36","author":"Zheng","year":"2023","journal-title":"Med Soc."},{"key":"B44","volume-title":"A Catalyst for Reform: Charting a Future for Orphan Drug Exclusivity","author":"Cohen","year":"2025"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1180550","DOI":"10.3389\/fmed.2023.1180550","article-title":"Policy analysis in the field of rare diseases in China: a combined study of content analysis and Bibliometrics analysis","volume":"10","author":"Li","year":"2023","journal-title":"Front Med"},{"key":"B46","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.jval.2024.01.002","article-title":"Partial orphan cancer drugs: US food and drug administration approval, clinical benefit, trials, epidemiology, price, beneficiaries, and spending","volume":"27","author":"Michaeli","year":"2024","journal-title":"Value Health"},{"key":"B47","doi-asserted-by":"publisher","first-page":"698534","DOI":"10.3389\/fmed.2021.698534","article-title":"Regulatory standards in orphan medicinal product designation in the EU","volume":"8","author":"Tsigkos","year":"2021","journal-title":"Front Med"},{"key":"B48","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1377\/hlthaff.2017.1179","article-title":"Evaluating the impact of the orphan drug act's seven-year market exclusivity period","volume":"37","author":"Sarpatwari","year":"2018","journal-title":"Health Aff"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1520467","DOI":"10.3389\/fpubh.2025.1520467","article-title":"Quantifying hope: an EU perspective of rare disease therapeutic space and market dynamics","volume":"13","author":"Cacoub","year":"2025","journal-title":"Front Public Health"},{"key":"B50","unstructured":"Nemoto\n              H\n            \n            \n              Yamada\n              T\n            \n            \n              Ueno\n              S\n            \n          \n          Market Exclusivity for Pharmaceutical Products in Japan\n          \n          2020"},{"key":"B51","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1186\/s13023-022-02456-w","article-title":"Lifecycle management of orphan drugs approved in Japan","volume":"17","author":"Seki","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.60095\/XAXH7327","author":"Dang","year":"2024","journal-title":"Scope of Exclusivity Under the Orphan Drug Act After Catalyst"},{"key":"B53","doi-asserted-by":"publisher","first-page":"e0164681","DOI":"10.1371\/journal.pone.0164681","article-title":"Profitability and market value of orphan drug companies: a retrospective, propensity-matched case-control study","volume":"11","author":"Hughes","year":"2016","journal-title":"PLoS ONE"},{"key":"B54","unstructured":"Zhang\n            \n            \n              X\n            \n          \n          Health Frontier\n          \n          2025"},{"key":"B55","doi-asserted-by":"publisher","first-page":"203","DOI":"10.3784\/jbjc.202509040618","article-title":"China's rare disease treatment and management pattern and its international significance","volume":"41","author":"Xiangyu","year":"2026","journal-title":"Dis Surveill"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.healthpol.2009.12.001","article-title":"The US orphan drug act: rare disease research stimulator or commercial opportunity?","author":"Wellman-Labadie","year":"2010","journal-title":"Health Policy"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1080\/13696998.2025.2577514","article-title":"Toward an ethical future for orphan drugs: balancing access, affordability, and innovation","volume":"28","author":"Alum","year":"2025","journal-title":"J Med Econ"},{"key":"B58","doi-asserted-by":"publisher","first-page":"416","DOI":"10.3389\/fpubh.2019.00416","article-title":"A review of rare disease policies and orphan drug reimbursement systems in 12 Eurasian countries","volume":"7","author":"Czech","year":"2020","journal-title":"Front Public Health"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1474087","DOI":"10.3389\/fmed.2025.1474087","article-title":"Impact of changes in regulatory framework on approval of medicines for rare diseases and applicability to market access policies","volume":"12","author":"Brown","year":"2025","journal-title":"Front Med"},{"key":"B60","doi-asserted-by":"publisher","first-page":"2466380","DOI":"10.1080\/23995270.2025.2466380","article-title":"Orphan drugs approved in Canada: availability and additional therapeutic value","volume":"5","author":"Lexchin","year":"2025","journal-title":"Future Rare Dis."},{"key":"B61","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1186\/s13023-022-02476-6","article-title":"Social pharmaceutical innovation and alternative forms of research, development and deployment for drugs for rare diseases","volume":"17","author":"Douglas","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1296737","DOI":"10.3389\/fphar.2023.1296737","article-title":"Bridging the new drug access gap between China and the United States and its related policies","volume":"14","author":"Zhu","year":"2024","journal-title":"Front Pharmacol"},{"key":"B63","unstructured":"Evaluate\n              Pharma\n            \n          \n          2025 Orphan Drug Report: Are Orphans That Different? Evaluate\n          \n          2525"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1896433\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T05:56:13Z","timestamp":1784699773000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1896433\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":63,"alternative-id":["10.3389\/fmed.2026.1896433"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1896433","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"article-number":"1896433"}}